Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 2/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 6/20 | 0.34 |
| ▸ | HTR2C | P28335 | 5/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364740 | 0.82 | KMT2A (0.40) | KDM1A | |
| SCHEMBL12200056 | 0.74 | ADRB2 (0.45) | KDM1AADRB2TBXA2R | |
| SCHEMBL990798 | 0.74 | BCHE (0.57) | — | |
| SCHEMBL1680336 | 0.74 | BCHE (0.57) | — | |
| SCHEMBL3346743 | 0.74 | BCHE (0.57) | — | |
| Hydrochloric Acid SCHEMBL987382 | 0.73 | BCHE (0.56) | — | |
| Hydrochloric Acid SCHEMBL3654652 | 0.73 | BCHE (0.47) | ADRB2TBXA2R | |
| SCHEMBL1364229 | 0.71 | KMT2A (0.40) | KDM1A | |
| SCHEMBL1364766 | 0.70 | L3MBTL1 (0.43) | L3MBTL1KDM1AADRB2TBXA2RS1PR1 | |
| SCHEMBL948574 | 0.70 | MTNR1B (0.39) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067598-B2 | Heterofused piperidines as orexin antagonists | HOFFMAN-LA ROCHE INC. (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| EP-2144906-B1 | HETEROCYCLES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-06-15 | — | — | EP | disclosed |
| WO-2008122513-A1 | HETEROCYCLES AS OREXIN ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249125-A1 | HETEROCYCLIC DERIVATIVES AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, HRH3 | L3MBTL1 4164/4885KDM1A 1583/4885DAO 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.